Proton Therapy for Lung Cancer May Help Reduce Risk of Heart Diseases

PHILADEPHIA—Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases, suggests a new study from Penn Medicine. In a retrospective trial of more than 200 patients, mini-strokes were significantly less common among patients who underwent proton therapy versus conventional photon-based radiation therapy. Proton therapy patients also experienced fewer heart attacks.

Timothy Kegelman, MD, PhD, chief resident in the department of Radiation Oncology in the Perelman School of Medicine at the University of Pennsylvania, will present the findings on Sunday, October 25, at the American Society for Radiation Oncology virtual Annual Meeting (Abstract #1046).

“This shows us another potential benefit of proton therapy for lung cancer patients,” Kegelman said. “We know proton has the ability to minimize radiation doses to surrounding organs like the heart. And these latest findings suggest that sparing correlates with fewer cardiac problems compared to conventional therapy.”

Abigail T. Berman, MD, MSCE, as assistant professor of Radiation Oncology at Penn, serves as senior author on the study.

Cardiac toxicity from radiation therapy remains a significant concern for lung cancer patients. One strategy to minimize dose is the use of proton therapy, which has the ability to more precisely target tumors and spare adjacent vital organs and healthy tissue.

The study found that 1.1 percent of patients with locally advanced non-small cell lung cancer treated with proton therapy experienced post-treatment mini-strokes, also known as transient ischemic attacks, after a median follow up of 29 months compared to 8.2 percent of patients treated with photon radiation therapy. Myocardial infarctions were also less common in the proton therapy group compared to the photon group, though the difference was not statistically significant: 2.3 percent versus nine percent.

There was no difference in the number of cases of atrial fibrillation, coronary artery disease, heart failure, or stroke. The researchers continue to compare the two approaches by looking more closely at the severity of the cardiac events and radiation dose to specific parts of the heart. The analysis will help radiation oncologists have a better understanding of how to minimize these risks further with newer technologies.

A large prospective, international phase III clinical trial investigating the difference between proton therapy and photon therapy in lung cancer patients—which includes patients treated in Penn’s Roberts Proton Therapy Center—has also been underway since 2014. The expectation is that protons will reduce cardiac-related morbidity and mortality, which will translate into a higher cure rate, the authors said. The trial is expected to complete patient accrual in 2022.

This study is the first experience suggesting a benefit of proton therapy over intensity modulated radiotherapy, or IMRT, in reducing cardiac dose effects.

“While these findings are promising and add to growing evidence, more research and the results of the randomized trial will help us better determine and understand how treating with protons may reduce cardiac event risk,” Kegelman said.

Penn co-authors include Varsha Jain, Steven J. Feigenberg, Srinath Adusumalli, Amberly Mendes, Corey Langer, Roger Cohen, Rupal P. O’Quinn, Bonnie Ky, Michael J. Kallan, Srinivas Denduluri, Keith A. Cengel, Aditi Singh, Charu Aggarwal, Joshua Bauml, and William P. Levin

Kegelman will present the findings as an oral abstract at 1:00 p.m. EST in the virtual conference.

##

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.6 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $494 million awarded in the 2019 fiscal year.

The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is powered by a talented and dedicated workforce of more than 43,900 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2019, Penn Medicine provided more than $583 million to benefit our community.